MRNA vs RVMD
Moderna and Revolution Medicines, Inc., both Healthcare
Revolution Medicines, Inc. is the larger company at $35B against $25B. Over the past year RVMD returned +517% against +93% for MRNA. Ryufin's sector-relative Smart Score puts RVMD ahead, 10/10 against 9/10.
| Figure | MRNA | RVMD |
|---|---|---|
| Last close | $62.96 | $216 |
| Market cap | $25B | $35B |
| 1-year return | +93% | +517% |
| 5-year return | -81% | +635% |
| Ryufin Smart Scoresector-relative, 1–10 | 9/10 | 10/10 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Moderna
Revenue of $145M in Q2 2026, net income null. Its largest reported line is COVID19, 81% of the disclosed total.
Revolution Medicines, Inc.
Open these two in the interactive comparison to add more names, change the period or read the correlation.